Alzheimer Disease Screening Profile, CSF
52+ booked in last 3 daysOverview
Alzheimer’s disease is the most common cause of dementia leading to a gradual decline in memory, thinking ability, cognitive skills and daily activities. This may in turn also affect the mood, behaviour and social skills of the patient. Alzheimer’s most commonly occurs beyond 65 years, although in certain rare cases, it may occur in patients <50 years (early-onset Alzheimer’s). The most common cause of Alzheimer’s is the deposition of certain proteins known as amyloid proteins in the brain cells. Alzheimer's disease screening profile analyzes cerebrospinal fluid (CSF) for protein levels. This profile measures beta-amyloid (1-42), a protein linked to Alzheimer's plaques, alongside total tau or phosphorylated tau (p-tau), which indicates neurodegeneration. The ratio of beta-amyloid (1-42) to beta-amyloid (1-40) can further refine the diagnosis, helping distinguish Alzheimer's from other forms of dementia like vascular dementia.
Alzheimer Disease Screening Profile, CSF Price
Metropolis Healthcare is a leading diagnostics centre and pathology lab in India equipped with the latest state-of-the-art technologies that provides the Alzheimer Disease Screening Profile, CSF with a clear pricing structure.
The Alzheimer Disease Screening Profile, CSF Price in Mumbai is ₹ 13,250 .
We are committed to deliver accurate and quality results from the best labs in India with complete transparency regarding test cost and turnaround time. No matter where you are, we strive to offer patients high-quality service that is affordable and accessible.
Frequently Asked Questions
Alzheimer disease screening profile CSF measure levels of beta-amyloid protein and tau protein in the CSF sample.
- Although the provisional diagnosis of Alzheimer’s is majorly done based on the patient’s symptoms and radiological examination, the laboratory tests and CSF examination may further aid the diagnosis.
- The test may be done for early diagnosis of suspected Alzheimer's disease.
- To differentiate between Alzheimer’s induced dementia and vascular causes for dementia.
It is advised that patients with the following clinical signs and symptoms of Alzheimer’s should undergo testing for differential diagnosis:
- Memory loss or dementia (mainly recent or short term memory)
- Delayed thinking or processing skills
- Reduced cognition
- Difficulty reasoning and handling complex tasks.
- Language processing difficulties.
- Understanding visual form and space relationship.
- Changes in overall behavior and personality.
This test requires a CSF sample. A spinal needle is used and the patient's CSF sample is collected with the necessary aseptic precautions. Note: Sample collection is done by qualified healthcare providers within hospital or clinic settings. The lab is only responsible for the analysis and processing of the sample.
No special precautions are required.
The levels of beta-amyloid protein and tau protein in the CSF sample aids the diagnosis and to determine the prognosis.
Determination of beta-amyloid (1-42) with total tau or p-tau in the CSF supports early diagnosis of suspected Alzheimer's disease. The beta-amyloid (1-42)/beta-amyloid (1-40) ratio can improve the discrimination between Alzheimer's patients and vascular dementia.
- Alzheimer’s test
- CSF test for Alzheimer’s
Ratings & Reviews (0)
Why Metropolis?
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
We offer a comprehensive range of 4000+ clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease.